Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Eflornithine + SAM486 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Eflornithine | Iwilfin | DFMO|alpha-difluoromethylornithine | Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor that blocks polyamine production, resulting in reduced tumor cell proliferation (PMID: 32256343). Iwilfin (eflornithine) is FDA-approved for use in adult and pediatric patients with high-risk neuroblastoma who have responded to prior therapies (FDA.gov) | |
| SAM486 | SAM486 is an inhibitor of AMD1, which may result in delay of tumor development (PMID: 27012811, PMID: 32256343). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|